Patients across the country are filing Xarelto bleeding lawsuits after experiencing dangerous internal bleeding events after using the medication.

To accommodate the growing number of Xarelto bleeding lawsuits, several consolidated movements have been formed to conserve legal resources and to speed along the litigation process.

As of June 15, 2016, there are approximately 5,853 Xarelto bleeding lawsuits in MDL (multidistrict litigation) No. 2592, with new claims being filed on daily basis.

Currently the plaintiffs of MDL No. 2592 are awaiting for the beginning of the bellwether trials, which may set the tone of the continuing Xarelto litigation.

As mentioned before, patients filing Xarelto bleeding lawsuits have allegedly suffered uncontrollable internal bleeding incidents as a result of taking the anticoagulant.

Overview of Xarelto Bleeding Complications

Xarelto is a popular new generation anticoagulant which is popularly prescribed to patients with atrial fibrillation or who are at a high risk for stroke. It was approved by the FDA in 2011, and is manufactured as a joint effort between Johnson & Johnson and Bayer Pharmaceuticals.

It is important to note that at the time of its approval, its predecessor Pradaxa had been hit with similar allegations of uncontrollable bleeding events. Both Xarelto and Pradaxa work by inhibiting the body’s clotting ability, to maximize circulation and to minimize the risks of blood clot injuries.

However this means the body’s ability to heal itself during internal bleeding event, which it can with most internal bleeding injuries, is also inhibited and puts the patient’s life at risk without emergency intervention.

There is currently no widely available bleeding antidote in the case of Xarelto bleeding events, which can be fatal if not treated in time.

Each of the new generation anticoagulants was released into the anticoagulant market to directly compete with warfarin. Xarelto and its counterparts were advertised to be overtly superior to the original anticoagulant, and was prescribed in convenient single doses.

Warfarin patients have to adhere to frequent doctor visits for dose adjustments, while Xarelto and the newer blood thinners have no such requirements. However warfarin patients also have a widely available bleeding antidote in the form of vitamin K, in the case of internal bleeding.

The internal bleeding complications mentioned in Xarelto bleeding lawsuits include:

• Gastrointestinal Bleeding
• Brain Bleeding
• Spinal Bleeding

Each of these injuries are life threatening, but are allegedly not adequately disclosed to the patient resulting in numerous unexpected internal bleeding incidents.

The patients filing these Xarelto bleeding lawsuits each claim some form of negligence and failure to warn, with many of them stating they never would have taken Xarelto if they had known of the risks of internal bleeding.

Xarelto Bleeding Lawsuits

With the number of Xarelto bleeding lawsuits continuing to increase, consolidation is a good way to also avoid conflicting rulings from different judges and to cut down on the number of litigation resources needed to process the large claim amount.

While the outcome of bellwether trials is not binding to other claims, it may serve as a gauge for parties to see how the Xarelto litigation may go.